Evidence mapPaperPMID 21307840Full record

SynthesisKidney international2011

Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts.

Marije van der Velde, Kunihiro Matsushita, Josef Coresh, Brad C Astor, Mark Woodward, Andrew Levey, Paul de Jong, Ron T Gansevoort, Chronic Kidney Disease Prognosis Consortium, Marije van der Velde and 42 more

Registry-linked trialOpen access · bronzeAbstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Kidney international, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03480568 (A Phase III Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen), which is not on this map. Cited by 482 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
482citing papers in PubMed, 1 pooled it
41.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03480568 phase3recruitingstarted 2018, after this paper: background citation

A Phase III Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen: The Alidial Study

Ran2018Enrolled20Registered outcomes5Posted comparisons0ConditionsAtherosclerotic Disease, Hemodialysis, Hypercholesterolemia, Peritoneal DialysisArmsAlirocumab 150 MG/ML [Praluent]
Open the trial in the graph
3 · Its place in the literature

Who cites it

482 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,059 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Observational
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

422 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

52 authors at 4 institutions in 3 countries.

Marije van der VeldeDepartment of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Kunihiro Matsushita
Josef Coresh
Brad C Astor
Mark Woodward
Andrew Levey
Paul de Jong
Ron T Gansevoort
Chronic Kidney Disease Prognosis Consortium
Marije van der Velde
Kunihiro Matsushita
Josef Coresh
Brad C Astor
Mark Woodward
Andrew S Levey
Paul E de Jong
Ron T Gansevoort
Andrew Levey
Meguid El-Nahas
Kai-Uwe Eckardt
Bertram L Kasiske
Toshiharu Ninomiya
John Chalmers
Stephen Macmahon
Marcello Tonelli
Brenda Hemmelgarn
Frank Sacks
Gary Curhan
Allan J Collins
Suying Li
Shu-Cheng Chen
K P Hawaii Cohort
Brian J Lee
Areef Ishani
James Neaton
Ken Svendsen
Johannes F E Mann
Salim Yusuf
Koon K Teo
Peggy Gao
Robert G Nelson
William C Knowler
Henk J Bilo
Hanneke Joosten
Nanno Kleefstra
K H Groenier
Priscilla Auguste
Kasper Veldhuis
Yaping Wang
Laura Camarata
Beverly Thomas
Tom Manley
Johns Hopkins University · USUniversity Medical Center Groningen · NLThe University of Sydney · AUTufts Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Screening for chronic kidney disease is recommended in people at high risk, but data on the independent and combined associations of estimated glomerular filtration rate (eGFR) and albuminuria with all-cause and cardiovascular mortality are limited. To clarify this, we performed a collaborative meta-analysis of 10 cohorts with 266,975 patients selected because of increased risk for chronic kidney disease, defined as a history of hypertension, diabetes, or cardiovascular disease. Risk for all-cause mortality was not associated with eGFR between 60-105 ml/min per 1.73 m², but increased at lower levels. Hazard ratios at eGFRs of 60, 45, and 15 ml/min per 1.73 m² were 1.03, 1.38 and 3.11, respectively, compared to an eGFR of 95, after adjustment for albuminuria and cardiovascular risk factors. Log albuminuria was linearly associated with log risk for all-cause mortality without thresholds. Adjusted hazard ratios at albumin-to-creatinine ratios of 10, 30 and 300 mg/g were 1.08, 1.38, and 2.16, respectively compared to a ratio of five. Albuminuria and eGFR were multiplicatively associated with all-cause mortality, without evidence for interaction. Similar associations were observed for cardiovascular mortality. Findings in cohorts with dipstick data were generally comparable to those in cohorts measuring albumin-to-creatinine ratios. Thus, lower eGFR and higher albuminuria are risk factors for all-cause and cardiovascular mortality in high-risk populations, independent of each other and of cardiovascular risk factors.

Indexed as

Glomerular Filtration RateAdultAgedAlbuminuriaBiomarkersCardiovascular DiseasesCause of DeathChi-Square DistributionCohort StudiesCreatineDisease ProgressionFemaleHumansKidneyKidney DiseasesMaleBiomarkersCreatine

Identifiers

PMID21307840
OpenAlexW2053091007

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.